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Methods: We prospectively included patients admitted to our department for acute HF
or exacerbation of chronic HF between December 2010 and May 2011. We excluded
patients over 80 years old, those with severe renal failure (GFR 50ml/min/1.73 m2) or
severe worsening of renal function during hospitalization and patients having dysthyroid-
ism or under immunosuppressive therapy. A dosage of plasmatic cystatin C concentration
was done using particule-enhanced turbidimetric immunoassay method. The main
endpoint was death at a 120 days follow up.
Results: Sixty four patients were enrolled, aged 62.2  11.4 years, with a sex ratio of
1.56. Patients were at NYHA class III or IV at admission in 87% of cases, with an
ischemic etiology in 55% of cases. LVEF was 51.7  13.8% and GFR was 76  19.8
ml/min. Mean cystatin C was 1.42  0.37 mg/l. During follow-up, 10 (15.6%) patients
died. Higher levels of Cystatin C (third tertile) were associated with a significant increase
in mortality rate with an RR of 8 when moving from the first to the third tertile and a RR
of 3 when moving from the second to the third (p0.033). Prognostic value is uncertain
for milder elevations between the first and second tertiles (p0.45).
Conclusion: A high level of Cystatin C at admission is a strong predictor of 120-days
mortality among patients with HF. Discriminative value falls for milder elevations.
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Neointimal Contractility Inside Of Stent: IVUS Observation In a Porcine
Coronary Model
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Aims: QCA after intracoronary Acetylcholine (Ach) infusion is used to evaluate of
coronary vasomotor dysfunction following stent implantation, which diameter changes of
non-stented segment was observed. In this case study, IVUS was utilized to analyze the
vasomotion within stented segment in a porcine coronary artery model.
Methods and Results: Everolimus-eluting stent (3.0x18mm) was implanted to RCA with
S/A of 1.1:1. At 28d, vasomotion was assessed by infusion of Ach 10-6 M/ml 3 min followed
by NTG 200g. An IVUS catheter was inserted to the mid of the stented segment without
pullback. IVUS imaging was recorded before, during Ach infusion, as well as after NTG
infusion. Finally, the animal was terminated for histology and immunhistochemistry.
Angiographically, the RCA was widely patent with TIMI III flow post stent
implantation and at follow-up. Neointimal contraction and relaxation in response to Ach
and NTG were demonstrated by IVUS (Figures), which measured by the changes of
neointimal hyperplasia area (NIA), as well as luminal area (LA). The maximal NIA inside
of the stent was 1.3 fold increasing from its baseline level during Ach infusion. In counter
to increasing of neointimal area, the minimal LA was reduced 30%. Following NTG
injection, the NIA was returned to baseline level. The stent area (SA) from IVUS was
consistent during this provocative test. Histology demonstrated fibrocellular neointimal
formation in the stented vessel segment. Immunohistochemistry for -actin showed
positive smooth muscle cell staining in the neointima.
Conclusions: This is the first report using IVUS to observe vasomotion within stented
segment in porcine model at 28d. Our results showed that the neointima in the stented
segment had contractility in response to Ach challenge. Scaffolding by metal stent plays
a role to compromise the consequence of vessel spasm.
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Effectiveness Of Implementing A Therapeutic Hypothermia Protocol In Cardiac
Arrest Patients: A Singapore Tertiary Center Experience
Shir Lynn Lim, Benjamin Leong, Joshua P Loh, Toon Wei Lim
National University Health Systems, Singapore, Singapore
Introduction: Out of hospital cardiac arrest (OHCA) is a major cause of unexpected
deaths in Singapore with an OHCA survival-to-hospital-discharge rate of 2%. Thera-
peutic hypothermia is strongly recommended for comatose OHCA survivors. Despite
this, worldwide implementation of therapeutic hypothermia has been slow.
Aims: We aim to evaluate the effectiveness of protocolizing therapeutic hypothermia in
a large tertiary hospital and to describe the outcomes of OHCA following its implemen-
tation.
Methods: We evaluated 964 OHCA patients who presented to the Emergency
Department from April 2010 to July 2012. A protocol for therapeutic hypothermia was
implemented in June 2011. Data on patients’ demographics, initial rhythm of arrest, site
of care, institution of therapeutic hypothermia, and neurological outcome on discharge
were collected.
Results: From April 2010 to July 2012, 964 OHCA patients presented to the
Emergency Department and 160 patients survived to admission. The overall OHCA
survival-to-hospital-discharge rate was 3.4%; this rate was 2.0% in the first year and 5.1%
in the year following the implementation of a protocol (p value  0.014).
Younger age (odds ratio0.66 per 10 years, p0.003) and a presenting rhythm of
ventricular fibrillation/tachycardia (odds ratio7.13, p0.001) were strong predictors of
survival to discharge.
The overall rate of implementation of therapeutic hypothermia was 25.8%. Prior to the
implementation of a protocol in June 2011, only 8.8% of patients who survived to
admission had therapeutic hypothermia. This rate increased significantly to 35.7% in the
year following the implementation of a protocol (p value0.001).
A greater proportion of the patients in the hypothermia group were discharged with
good neurological outcome (15% versus 7.8%, p value  0.217), although the result was
not statistically significant.
Conclusion: The presence of a protocol led to increasing use of therapeutic hypothermia
for comatose OHCA patients in our intensive care units and may have contributed to an
improvement in the outcomes of OHCA patients.
Thrombosis
CRT-122
Pretreatment of Synthetic Vascular Grafts With Heparin Before Implantation, A
Simple Technique To Reduce The Risk of Thrombosis
Rabin Gerrah, Alan R. Hohimer, Rachel E. Sunstrom, Rich D. Reed, Stephen M. Langley
Oregon Health and Science University, Portland, OR
Background: Synthetic grafts are being widely used to bypass occluded vessels or to
supply blood flow. Thrombosis of these grafts is a major complication. The clots are often
formed during the first exposure of blood to the graft surface which later become a nidus
for larger clots. We examined whether pretreatment of the graft with heparin prevents this
initial clotting process.
Methods: A circuit was assembled to compare two sets of shunts in the same subject.
This circuit simulated a systemic-pulmonary shunt with inflow cannula in the aorta,
branching to 2 groups of study and control grafts, connected to an outflow cannula in the
pulmonary artery. The study group was treated with heparin for 15 minutes prior to
placement in the circuit. With installation of the circuit, the blood flowed from the aorta
to a set of multiple branches all the same size and properties with the only difference being
exposure to heparin.
Pressure was monitored proximal and distal to the branches to verify similar flow
dynamics in each group. After 2 hours of simultaneous and equal flow in all branches the
circulation was discontinued and the grafts were irrigated and sliced open to expose the
inner surface. Digital images were taken in a standard technique coded for each graft for
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a blinded analysis. The images were analyzed by image analysis software. The density and
area of the pixels was proportionate to the amount of the clot formed on the graft surface.
Results: The pressure gradient between the groups was identical throughout the study,
meaning similar flow characteristics were maintained in all branches. The pretreated grafts
had fewer blood clots adhered to the surface by direct visual inspection. The image analysis
showed 5 vs.39 clots, 0.01% vs. 1.8% clotted area and 62 vs. 5630 clot pixel area between
the treated and non-treated grafts respectively, p 0.05.
Conclusion: Pretreatment of the synthetic graft with heparin prior to implantation
reduces the risk of early clot formation. This simple practice might be helpful to prevent
initial thrombosis of the graft and later occlusion especially in critical situations where the
patency of the graft is crucial.
TECHNOLOGY
Drug Coated Balloons
CRT-123
A Novel Nano Particle Sirolimus Delivery Via Coated Balloon
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Objectives: Objective of this study was to develop non-polymeric sirolimus nanoparticle
coated balloon and demonstrate in-tissue transfer through DCB in rabbit model.
Background: Drug coated balloon (DCB) is an emerging technology. To date paclitaxel
is a choice in DCB. Due to lipophilic properties of sirolimus, short time delivery through
DCB is a major challenge. To overcome current limitations, we hypothesized; nanopar-
ticle sirolimus coated on the balloon can provide better delivery and retention.
Methods: We prepared phospholipid encapsulated sirolimus and coated on the balloon
with novel coating formulation. The characteristics of the nanoparticle sirolimus DCB
was tested in both an in-vitro and preclinical in-vivo models. New Zealand rabbits
underwent drug coated balloon dilatation in iliac arteries for pharmacokinetics, confocal
microscopy and scanning electronic microscopy studies.
Results: Sirolimus nanoparticles were	400nm with stable solution. Coating surface was
smooth without defect and irregularities. In-tissue uptake of sirolimus was at 1, 7 and 14
days with concentration of 140.6, 15.5 and 5.5 ng/mg, respectively. Sirolimus coated
balloon with 3x inflations was also safe in the rabbit iliac arteries. Confocal microscopy
showed homogeneous fluorescent tagged nano sirolimus (DTF-nSRL) distribution into
the artery wall with intima to adventitia flow. None of the in-vivo investigation has
reflected emboli in downward stream.
Conclusion: Present set of experiments showed adequate amount of sirolimus was
delivered through non-polymeric DCB. Multiple inflation demonstrated safety to
co-relate with actual clinical outcome. Confocal imaging has showed homogenous
distribution in cross section and longitude parts. Path of drug travel was to the deepen area
of arterial wall upon time from intima to adventitia (Table 1).
Table 1. Depth of DTF-nSRL signal punctuation in rabbit iliac arteries
Time Point 24 hour 3 day 7 day
Depth of penetration 10-20m 10-30m 10-40m
Drug Eluting Stents
CRT-124
Comparative In Vitro Effects Of Paclitaxel, Everolimus, And Tacrolimus On
Macrophage-derived Foam Cells, Smooth Muscle Cells, And Endothelial Cells
Steven Hsu, Eugen Koren, Yen Chan, Mirna Koscec, Debby Feder
Abbott Vascular, Santa Clara, CA
Background: Macrophage-derived foam cells (FC) play a key role in atherosclerotic
lesion progression. Effects of different drugs used in drug-eluting stents (DES) on FC
behavior have not been well characterized. We used an in vitro model to compare effects
of paclitaxel, everolimus, and tacrolimus on FC, human coronary endothelial cell
(HCAEC), and human coronary smooth muscle cell (HCASMC) viability, FC gene
expression, and FC inflammatory cytokine levels.
Methods: FC were derived from human THP1 macrophages with acetylated LDL,
followed by treatment with paclitaxel, everolimus, or tacrolimus (10-5-10-11M) for 24 hrs
(n4). HCAEC and HCASMC were similarly treated with all three drugs. Cell lysates
and media supernatants were analyzed for apoptosis/necrosis using a Cell Death
Detection ELISAPLUS (Roche, Pleasanton, CA) assay. FC lysates were also evaluated
for apoptosis (survivin, clusterin) and autophagy (MAP1LC3) gene expression via a
Quantigene® Plex assay (Affymetrix, Santa Clara, CA). FC supernatants were analyzed
for MCP1 levels via a Procarta® mmunoassay (Affymetrix). Statistical significance was set
at p0.05 by ANOVA/Holm’s t-test.
Results: FC apoptosis was significantly increased compared to control at 10-5M for both
everolimus and paclitaxel, with no effects on FC necrosis for both drugs. Tacrolimus did
not affect FC apoptosis or necrosis. Paclitaxel (10-5M) significantly increased clusterin and
decreased survivin expression in FC. Tacrolimus did not affect gene expression while
everolimus (10-5M) significantly increased MAP1LC3 and clusterin (p0.10) and
decreased survivin expression in FC. Everolimus (10-5M) significantly decreased MCP1
in FC supernatants. Effects of all three drugs on HCASMC and HCAEC viability were
also explored. While everolimus and tacrolimus did not affect apoptosis or necrosis,
paclitaxel (10-5M) significantly increased HCASMC and HCAEC apoptosis and
necrosis.
Conclusion: The three drugs explored in this study have variable effects on FC,
HCASMC, and HCAEC. Unlike paclitaxel and tacrolimus, everolimus may inhibit FC
accumulation in atheromas through selective autophagy/apoptosis of FC and inhibition of
monocyte recruitment into the arterial wall.
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Do Second-Generation Drug-Eluting Stents Outperform First-Generation Drug-Eluting
Stents When Used in “Full Metal Jacket” Percutaneous Coronary Intervention
Procedures?
Joshua P Loh, Lakshmana K Pendyala, Hironori Kitabata, Salem M Badr,
Sa’ar Minha, Danny Dvir, Israel M Barbash, Rebecca Torguson, Lowell F Satler,
Kenneth M Kent, William O Suddath, Augusto D Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC
Background: Diffuse coronary lesions are often treated with long and overlapping
drug-eluting stents (DES) creating a full metal jacket, however the impact on clinical
outcomes comparing different generation DES has not been described.
Methods: We conducted a retrospective analysis of 98 patients with full metal jacket
stenting, defined as the total and continuous stent length of  50 mm in a single vessel,
treated using either first-generation (sirolimus- and paclitaxel-eluting) DES or second-
generation (everolimus-eluting) DES.
Results: Full metal jacket stenting was performed in 36 patients/71 lesions with
second-generation DES (Xience V or Promus); and 62 patients/151 lesions with
first-generation DES (Cypher or Taxus). Baseline characteristics were similar between the
groups. More second-generation DES were used per patient than first-generation DES
(3.2 vs. 2.6, p0.001); mean stent length (23.9 vs. 25.3mm) and diameter (2.9mm in
both) were similar (pNS). Angiographic success was 100% in both groups. At 1-year
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